BANGKOK, Nov. 18, 2024 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), today announced that it has entered into a binding term sheet (the "Term Sheet") with White Lion Capital, LLC, ("White Lion") a California-based institutional investor focused on high-growth, early-stage public companies, setting out the principal terms and conditions for a $100 million equity line of credit, expandable to $500 million. Pursuant to the Term Sheet, NewGen will have the option, but not the obligation, to sell to White Lion up to $100.0 million in shares of common stock over an initial 36-month period, with the potential to increase to $300.0 million upon substantial

BANGKOK, Oct. 14, 2024 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), today announced that on October 8, 2024, the Company received a letter (the "Deficiency Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is currently not in compliance with the closing bid price requirement under Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule"). The Deficiency Letter notified the Company that, for the preceding 30 consecutive business days, the Company's Class A Ordinary Shares (the "Class A Shares") did not meet the minimum closing bid price of $1 per share pursuant to

Total Revenues Reach US$5.1 MillionGross Profit Increases by 9.4% to US$1.7 MillionNet Income of US$0.1 million BANGKOK, Thailand, Aug. 21, 2024 (GLOBE NEWSWIRE) -- NewGenIvf Group (NASDAQ:NIVF) ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that on August 19, 2024, the Company filed its 2023 annual report (20-F) with the SEC. 2023 Financial Highlights Total revenues were US$5.1 million in the full year of 2023.Gross profit increased by 9.4% to US$1.7 million from US$1.5 million in the full year of 2022.Gross margin was 32.8%, compared to 25.9% in the full year of 202

BANGKOK, July 24, 2024 (GLOBE NEWSWIRE) -- NewGenIvf Group (NASDAQ:NIVF) ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced an update on its proposed reverse merger (the "Proposed Transaction") with pharmaceutical company COVIRIX Medical Pty Ltd ("COVIRIX"). The Company reports steady progress in its due diligence efforts and, contingent upon meeting all regulatory requirements, anticipates completing the Proposed Transaction by the end of August 2024. Mr. Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGen, commented, "We are very encouraged by the progress of our d

BANGKOK, June 20, 2024 (GLOBE NEWSWIRE) -- NewGenIvf Group (NASDAQ:NIVF) ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that the Company is continuing to actively evaluate the terms of the proposed reverse merger (the "Proposed Transaction") with COVIRIX Medical Pty Ltd ("COVIRIX"). NewGen and COVIRIX (collectively, the "Parties") have conducted due diligence on each other's business and are continuing to make solid progress towards satisfying the preconditions for completion of the Proposed Transaction. The Parties are targeting completion of the non-binding term sheet

BANGKOK, Thailand, June 03, 2024 (GLOBE NEWSWIRE) -- NewGenIvf Group (NASDAQ:NIVF) ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced the execution of a non-binding term sheet (the "Term Sheet") regarding a proposed reverse merger (the "Proposed Transaction") with pharmaceutical company COVIRIX Medical Pty Ltd ("COVIRIX"). Mr. Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGen commented, "I am excited to announce that we have executed a non-binding term sheet to pursue a proposed reverse merger with COVIRIX, a pharmaceutical company developing novel antiviral therap

BANGKOK, May 28, 2024 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), today announced that on May 24, 2024, the Company received two letters from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is currently not in compliance with certain requirements under the relevant Nasdaq Listing Rules. The first letter (the "MVPHS Deficiency Letter") notified the Company that, for the preceding 35 consecutive business days of the MVPHS Deficiency Letter, the Company's Class A Ordinary Shares (the "Class A Shares") did not meet the minimum $15,000,000 Market Value of Publicly Held Shares ("MVPHS") requ